The global, strategic, multi-target collaboration and license agreement with Takeda was announced in October 2016.
Under this agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to identify and optimally configure Humabody based therapeutics against targets selected by Takeda.
This milestone, for an undisclosed amount, marks the successful delivery of a highly diverse panel of Humabody leads, directed to the first of Takeda’s selected targets.
Dr Peter Pack, CEO of Crescendo, commented: “This milestone is an important step forward in our relationship with Takeda. It demonstrates our ability to deliver a diverse selection of characterised Humabody molecules that meet the stringent specifications outlined in the agreement."
"In conjunction with Takeda’s deep expertise in the field of oncology, this exciting milestone provides further validation of Crescendo’s ability to create optimally configured Humabodies."
“This milestone demonstrates the potential of this innovative technology and brings us closer to our goal of developing next generation, highly modular and targeted biologics against cancer.”
